Annual Report 2002 - Agfa
Annual Report 2002 - Agfa
Annual Report 2002 - Agfa
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS<br />
The reconciliation of Cash and cash equivalents with its corresponding balance<br />
sheet items can be presented as follows:<br />
16. Cash and cash equivalents<br />
MILLION EUROS <strong>2002</strong> 2001<br />
Marketable securities and other instruments 12 2<br />
Cash on hand, demand deposits and checks 133 222 *<br />
Total Cash and cash equivalents as reported<br />
in the Balance Sheet 145 224<br />
Accounts receivable under cash management agreements<br />
(reported in the balance sheet as Other receivables) - 3<br />
Liabilities under cash management agreements<br />
(reported in the balance sheet as Miscellaneous liabilities) (4) (7)<br />
Revaluation financial assets available-for-sale - 3<br />
Total Cash and cash equivalents as reported<br />
in the Cash Flow Statement 141 223<br />
* Included is an amount of 97 million Euros that has been deposited into an escrow<br />
account in relation to the acquisition of Mitra Inc. This amount represented<br />
a portion of the purchase price of Mitra Inc. (note 4).<br />
The various components of Shareholders’ Equity and the changes therein from<br />
December 31, 2001 to December 31, <strong>2002</strong> are presented in the Consolidated<br />
Statements of Shareholders’ Equity.<br />
17. Shareholders’ equity<br />
Capital stock<br />
The issued capital of the Company as of December 31, <strong>2002</strong> amounts to 140 million<br />
Euros, represented by 140,000,000 fully paid ordinary shares without par value.<br />
Reserve for own shares<br />
The reserve for the Company’s own shares comprises the cost of the Company’s<br />
shares held by the Group. At December 31, <strong>2002</strong> the Group held 768,400<br />
(2001: 150,000) of the Company’s shares (note 18 B).<br />
Revaluation reserve<br />
In order to manage the price risk on its Long Term Incentive Plan (tranche n° 2)<br />
the Company deposited 10.2 million Euros, pledged in favour of an investment<br />
banker. This available-for-sale financial asset was revalued to fair value with<br />
cumulative changes taken into the revaluation reserve (note 18 B).<br />
The revaluation reserve moreover comprises the revaluation of our investment in<br />
Medivision Medical Imaging Ltd. (December 31, <strong>2002</strong>: -2 million Euros).<br />
<strong>Agfa</strong> annual report <strong>2002</strong><br />
70